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Available online 5 October 2006Edited by Peter BrzezinskiAbstract The plasmepsin proteases from the malaria parasite
Plasmodium falciparum are attracting attention as putative drug
targets. A recently published crystal structure of Plasmodium
malariae plasmepsin IV bound to an allophenylnorstatine inhib-
itor [Clemente, J.C. et al. (2006) Acta Crystallogr. D 62, 246–
252] provides the ﬁrst structural insights regarding interactions
of this family of inhibitors with plasmepsins. The compounds in
this class are potent inhibitors of HIV-1 protease, but also show
nM binding aﬃnities towards plasmepsin IV. Here, we utilize
automated docking, molecular dynamics and binding free energy
calculations with the linear interaction energy LIE method to
investigate the binding of allophenylnorstatine inhibitors to
plasmepsin IV from two diﬀerent species. The calculations yield
excellent agreement with experimental binding data and provide
new information regarding protonation states of active site resi-
dues as well as conformational properties of the inhibitor com-
plexes.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Structure-based drug design strongly relies on the availabil-
ity of three-dimensional molecular structures of the biological
targets of interest. The methods for structure determination
provide experimental data (i.e., electron density maps, NMR
spectra) that need to be processed in order to obtain ﬁnal
molecular models. It follows that structural and computational
analysis of the reported structures can provide deeper knowl-Abbreviations: Apn, allophenylnorstatine; LIE, linear interaction ene-
rgy; MD, molecular dynamics; PmPM IV, Plasmodium malariae pla-
smepsin IV; PfPM IV, Plasmodium falciparum plasmepsin IV; RMSD,
root mean square deviation
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doi:10.1016/j.febslet.2006.09.057edge about protein–ligand interactions, and sometimes also a
quantitative energetic description of relevant interactions
responsible for binding aﬃnity. One example of such eﬀorts
is the structure based design of antimalarial drugs that inhibit
the aspartic proteases of the Plasmodium species known as
plasmepsins (PM) [1–3].
This family of enzymes, together with cysteine proteases
and metalloproteases, are responsible for the degradation of
hemoglobin by the parasite, which occurs in the acidic food
vacuole during the intraerythrocytic stage of the life cycle
[4]. Four plasmepsins exist in the food vacuole of Plasmodium
falciparum, the most lethal species and responsible for the
majority of the malaria related deaths, named PfPM I to
PfPM IV [5]. All plasmepsins are aspartic proteases except
for the histo-aspartic protease (HAP, or PfPM III) [6] and
share more than 68% of sequence identity [7]. Among them,
PfPM IV is the ortholog of the unique plasmepsin present in
the food vacuole of the other three species infecting man
(Plasmodium malariae, PmPM IV; Plasmodium vivax, PvPM
IV; and Plasmodium ovale, PoPM IV) [8]. The identity among
PM IV from these diﬀerent species is between 70% and 87%
[7]. Therefore, there is a growing interest in the structural
characterization of this class of enzymes to aid structure-
based drug design. There exist crystal structures of PfPM
IV (PDB entry 1LS5) [9] and PvPM IV (PDB entry 1QS8)
[10] in complex with the canonical peptide-mimetic inhibitor
pepstatin A. Very recently, a low resolution crystal structure
of PmPM IV in complex with an allophenylnorstatine inhib-
itor was published (PDB code 2ANL) [11]. The allophenyl-
norstatine (Apn) series of inhibitors were initially developed
by Kiso and co-workers towards HIV protease [12]. The
potential application of this chemical scaﬀold for develop-
ment of new plasmepsin ligands was soon appreciated [13],
and considerable eﬀorts have been devoted to lead optimiza-
tion towards these biological targets [3,14]. The binding mode
of this class of compounds was previously hypothesized by
molecular modeling [3], but these predictions seem incompat-
ible with the new crystal structure of the PmPM IV–KNI764
complex [11]. Here, we present a computational analysis of
the binding mode proposed by Clemente and co-workers
[11] for the Apn inhibitor KNI764, extending their model
to other Apn inhibitors and to the corresponding P. falcipa-
rum enzyme (PfPM IV). We ﬁnd that consistence with experi-
mental data can be found only after some considerations
that aﬀect the detailed nature of ligand–protein binding
contacts.blished by Elsevier B.V. All rights reserved.
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All molecular alignments, manipulation of chemical structures and
the generation of ﬁgures were done with the software Pymol v0.99 [15].
2.1. Automated docking
Automated docking exploration was performed with GOLD version
3.0.1 [16], allowing full ﬂexibility for the ligand while keeping the pro-
tein ﬁxed (i.e., only rotation of the protein hydroxyl groups was con-
sidered). The docking exploration consisted of 20 independent runs
with each compound, using the default genetic algorithm (GA) search
parameters. Both scoring functions implemented in the program
(Chemscore and Goldscore) [17] were considered in parallel runs.
The automated assignment of protein and ligand atom types was
checked in order to ensure a correct treatment of the potential hydro-
gen bond donors and acceptors. In all cases, the protein model used
was PmPM IV (PDB entry 2ANL). This choice was based on the
observation that there is conformational variability of plasmepsins
depending on the inhibitor bound [18–20]. Therefore, the conforma-
tion adopted upon binding to KNI764 is the most reasonable protein
structure for the purpose of docking a set of Apn inhibitors. The dock-
ing into PfPM IV was done by superimposing the resulting inhibitor-
2ANL complex on the crystal structure of PfPM IV (PDB entry
1LS5). Docking solutions were selected for post-processing only if they
satisﬁed the following conditions: (i) The existence of at least one inter-
action between the allophenylnorstatine hydroxyl with the catalytic
aspartates and (ii) the best ranked representative of the cluster should
be among the 25% top scoring solutions (clustering was done accord-
ing to a 1.5 A˚ RMSD clustering criterion).2.2. Molecular dynamics (MD) and binding free energy calculations
Binding aﬃnities were calculated using the linear interaction energy
(LIE) method, described in detail elsewhere [21,22]. Basically, this ap-
proach estimates the ligand free energy of binding from the diﬀerence
in the ligand-surrounding interaction energies between its bound and
free state. The relationship between the ligand intermolecular inter-
action energies and the free energy of binding is given by the equation:
DGbind ¼ aDhV vdWls i þ bDhV ellsi þ c ð1Þ
where V vdWls and V
el
ls denote, respectively, the Lennard-Jones and elec-
trostatic interactions between the ligand and its surroundings (l  s).
These interactions are evaluated as energy averages (denoted by the
open brackets) from separate MD simulations of the free (solvated
in water) and bound states. The diﬀerence (D) between such averages
for each type of potential is scaled by diﬀerent coeﬃcients (see Ref.
[22]), giving the polar and non-polar contributions to the binding free
energy. For the non-polar contribution, this coeﬃcient has been empir-
ically set to a = 0.181, while for the polar contribution the scaling fac-
tor is dependent on the chemical nature of the ligand. For ligands with
one hydroxyl group (KNI727), the value is b = 0.37, while for the
ligands with two or more hydroxyls the value is b = 0.33 [22].
MD simulations were done using the program Q [23] and the OPLS
force ﬁeld there implemented [24]. Parameters for the ligands which
were not included in our implementation of the force ﬁeld were derived
manually, following the rules of the original OPLS force ﬁeld. The
system was solvated with a simulation sphere of TIP3P waters [25]
of radius 20 A˚, centered on the carbon of the transition state mimic hy-
droxyl. The water surface of this sphere was subjected to radial and
polarization restraints [26] in order to mimic bulk water at the sphere
boundary. Non-bonded interaction energies were calculated up to a
10 A˚ cutoﬀ, except for the ligand atoms for which no cutoﬀ was used.
Beyond the cutoﬀ, long-range electrostatics were treated with the local
reaction ﬁeld (LRF) multipole expansion method [27]. Protein atoms
outside the simulation sphere were restrained to their initial positions,
and only interacted with the system through bonds, angles and tor-
sions. For the ligand–protein simulations, a heating and equilibration
procedure was applied before the data collection phase. The equilibra-
tion protocol started with 1000 steps MD using very short time step
(0.2 fs) at 1 K temperature, coupled to a strong bath (0.2 fs bath cou-
pling) with positional restraints on heavy atoms. Then the system was
gradually heated up to 300 K, relaxing the temperature bath coupling
to 100 fs and increasing the timestep to 1.5 fs. During this equilibration
process positional restraints on the protein heavy atoms and the cen-
tral atom of the ligand were gradually released from 200 to 0 kcal/(mol A˚2). In the case of the crystallized complex (2ANL), all ligand
heavy atoms were also subjected to the same restraint as the protein
atoms. The production phase followed for 0.3–1.2 ns making use of
the SHAKE algorithm [28] for the treatment of the bond lengths
and collecting energies at regular intervals of 15 fs. Stability was ad-
dressed by comparing the average potential energy values of the ﬁrst
and second halves of the data collection period, which yields the esti-
mated error in the calculation of the corresponding potential energy.
Error estimates in the calculated free energies were obtained by adding
the errors in the potential energy from both the water and protein sim-
ulations, properly scaled through the use of the LIE a and b factors.
Trajectory lengths yielding errors in the potential energies not larger
than 1 kcal/mol were generally accepted, since the computed error in
the calculated free energy of binding then is less than 1 kcal/mol.
The MD sampling of the free ligand was again done in a TIP3P
water sphere of the same radius as in the corresponding protein simu-
lation. The sphere was equilibrated with a 10.2 ps MD run at 300 K,
with positional restraints on the heavy atoms of the ligand (200 kcal/
(mol A˚2) for the ﬁrst 0.2 ps and 10 kcal/(mol A˚2) in the following
10 ps). MD simulation then followed for at least 1.5 ns under the same
conditions as for the bound state, but keeping the initial position of the
central atom of the ligand ﬁxed with 10 kcal/(mol A˚2) to ensure homo-
geneous solvation.3. Results
The recent crystal structure of PmPM IV in complex with
KNI764 [11] was analyzed by MD simulations, and the bind-
ing free energy of the inhibitor was estimated with the LIE
method. The protonation state of the catalytic aspartates
was initially retrieved from earlier works [2,29], with the pro-
ton located on the oxygen of Asp34 (Od2) closest to Asp214
(hereafter referred to as model AspH34, see Fig. 1A). The pro-
posed inhibitor position remained stable along the simulation,
and up to eight hydrogen bonds (H-bonds) are detected be-
tween the ligand and protein (see Fig. 1C). Despite this exten-
sive H-bond network, the calculated electrostatic component
of the binding free energy remained positive (unfavorable).
The reason for this unexpected result was found in the low
absolute energy of interaction of the ligand with the negatively
charged Asp214, which in previous calculations [2,29] was in
the range of 20 to 30 kcal/mol (Gutie´rrez-de-Tera´n and
Nervall, unpublished observations), while in the present case
the aforementioned interaction energy was only about
5 kcal/mol. The estimated free energy of binding was there-
fore dominated by the hydrophobic contribution and the
calculated value is shifted by about 6 kcal/mol from the exper-
imental value (see Table 1). Since the estimation of absolute
binding aﬃnities with the LIE method may require the inclu-
sion of a constant term, which is dependent on the nature of
the protein [30], other PM IV inhibitors were examined for rel-
ative aﬃnities. We selected KNI577, a much less potent inhib-
itor of PmPM IV (Ki = 3 lM) [11], since the small structural
diﬀerence with KNI764 made it straightforward to perform
manual docking into the 2ANL crystal structure. Additionally,
the ortholog enzyme in P. falciparum (PfPM IV) was explored
with another pair of inhibitors presenting a signiﬁcant diﬀer-
ence in the experimental aﬃnity for this enzyme [3]:
KNI10006 (IC50 = 15 nM) and KNI727 (IC50 = 740 nM).
The chemical structures of the four inhibitors are shown in
Fig. 2. Initially, manual docking was done by structural super-
position of 2ANL onto 1LS5 followed by manual modiﬁcation
of the corresponding P2 and P2 0 chains of KNI764. In neither
of the two PM IV enzymes (P. falciparum or P. malariae) did
we ﬁnd any correlation with the relative aﬃnities for each pair
Fig. 1. Top: initial H-bond network of 2ANL complex with a proton located on Asp34 (A) or Asp214 (B). Bottom: average structures after MD
sampling of the two models: AspH34 (C) or AspH214 (D).
Table 1
Experimental and calculated free energies of binding (in kcal/mol) of
the four PMIV–KNI complexes
Complex DGobsbind
a DGcalcbind AspH214 DG
calc
bind AspH34
KNI764–PmPMIV 9.6b 9.8 ± 0.7d 3.0 ± 0.4
KNI577–PmPMIV 7.6b 7.0 ± 0.8 4.3 ± 0.8
KNI10006–PfPMIV 10.7c 14.1 ± 0.4 5.9 ± 0.2
KNI727–PfPMIV 8.4c 11.9 ± 0.5 5.9 ± 0.6
aThe binding free energy calculated from experimentally determined
Ki’s using DG
0
bind; exp ¼ RT lnK i.
bValues from Ref. [11].
cValues from Ref. [3].
dAverage value from two MD simulations: starting from the crystal-
lographic coordinates and from the GOLD predicted pose.
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tribution from the electrostatic component of the binding free
energy was observed. In particular, the electrostatic interac-
tions of the ligand with the catalytic aspartates were rather
small (see Table 2).
Attempts to re-dock KNI764 into PmPM IV resulted in the
identiﬁcation of several binding modes. Only the pose ranked
#7 using the Goldscore function showed some similarity to the
crystallographic pose, with an RMSD of 2.7 A˚. The binding
mode previously hypothesized by Nezami et al. [3] was among
the top ranked solutions (#1 with Chemscore and #3 with
Goldscore). This position involves a 180 turn along the
prime–non-prime axis with respect to the binding mode shown
in the crystal structure. However, this orientation of the ligand
is hardly compatible with the 3.3 A˚ electron density map of the
PmPM IV-KNI764 complex deposited in the PDB [11].According to the 2ANL crystal structure, the pair distances
between the Od atoms of the catalytic aspartates and the het-
eroatoms of the ligand (the transition state mimic hydroxyl
and the adjacent oxygen O23) are compatible with diﬀerent
hypotheses for the protonation state of the catalytic aspartates.
Our ﬁrst model (AspH34) was unsuccessful in reproducing
absolute as well as relative binding aﬃnities. Consequently,
the next step was to explore alternative protonation states.
Fig. 1B shows how the location of the proton on the most ex-
posed oxygen of Asp214 (hereafter referred to as the AspH214
model) can lead to a strong H-bond network between the Apn
core and the catalytic center. Moreover, the electronic repul-
sion between a negatively charged aspartate and the carbonyl
of the P1 0 amide bond (O23), present in the previous AspH34
model, is not observed and instead O23 accepts two H-bonds
from AspH214 and Thr217.
In order to check the reliability of this hypothesis, we re-
peated MD simulations of the 2ANL structure according to
the AspH214 model. This time, the estimation of the free en-
ergy of binding was extremely accurate, and some interesting
conformational rearrangements of the ligand and protein side-
chains were observed (see Fig. 1D). The P2 amide bond ﬂips at
the very beginning of the simulation, remaining stable in the
new position for the rest of the simulation. This allowed the
formation of H-bonds in P2 with Ser79 in the ﬂap and
Thr217, after some reorientation of the sidechain of the latter
residue. Asp214 ﬂips 90 to avoid electrostatic repulsion with
Asp34, maintaining an H-bond to the carbonyl in the P1 0
amide bond, while the hydroxyl group of the inhibitor H-
bonds to the negatively charged Asp34. The interactions at
the prime side remain unchanged with respect to the previously
described simulation using the AspH34 model. As can be
Fig. 2. Structures of the four PMIV inhibitors considered in this work.
Table 2
Interaction energies (kcal/mol) between the catalytic aspartates and the ligand
Complex hV ellAsp’si DDGelAsp’sa DGelbindb
AspH214 AspH34 AspH214 AspH34
KNI764–PmPMIV 27 16.5 3.9 4.9 +2.0
KNI577–PmPMIV 20 21.5 0.5 1.8 +0.1
KNI10006–PfPMIV 32 20.5 3.8 7.9 0.3
KNI727–PfPMIV 35 24 3.6 6.5 0.5
aDiﬀerence in the electrostatic component of the binding free energy due to interactions of the ligand with the catalytic aspartates, calculated as:
DDGelAsp’s ¼ bðhV ellAsp’siAspH214  hV ellAsp’siAspH34Þ. Note that a negative sign indicates favored binding for the AspH214 model.
bElectrostatic component of the total binding free energy, calculated as DGel ¼ bðhV ellsip  hV ellsiwÞ.
Fig. 3. Plot of the diﬀerence in accumulated average non-bonded
ligand–protein interactions between the two trajectories of the
KNI764–PmPMIV complex (using the AspH214 and AspH34 models).
A more negative value indicates favored interactions for the AspH214
model. Dashed lines account for electrostatic interaction energy, while
solid lines indicates non-polar energy. The residues responsible of the
biggest diﬀerences are indicated.
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for stronger electrostatic interactions between ligand and pro-
tein, since the H-bond network is more complete than in the
AspH34 model.The AspH214 model was subsequently used for new docking
explorations. Interestingly, both Goldscore and Chemscore
functions showed high sensitivity to this change, and the native
pose was now found in the ﬁrst (Chemscore) and second
(Goldscore) ranking position. The RMSD with respect to the
crystallographic pose was 1.0 and 0.9 A˚, respectively. Interest-
ingly, the amide bond in P2 was ﬂipped in agreement with the
MD simulations of the 2ANL complex. We repeated the MD
simulation of PmPM IV-KNI764 complex, using the ligand
conformation predicted by GOLD. The predicted free energy
of binding was very accurate again (DGbind,calc = 10.0 kcal/
mol) and the superposition of the average structure of the com-
plex with the electron density map of 2ANL is depicted in
Fig. 4. The orientation of the sidechains of both Asp214 and
Thr217 this time shows good agreement with the electron den-
sity, although a slight deviation of the 2-methylbenzyl ring
with respect to the mesh can be observed.
Docking of the less active ligand KNI577 pointed in the
same direction, and again both scoring functions identiﬁed
the same binding mode as described above for KNI764. MD
simulation of this binding orientation of KNI577 demon-
strated the stability of the complex, with the calculated value
for the free energy being very close to the experimental value.
The major diﬀerences with respect to KNI764 were found in
the electrostatic interactions with Asp214 and Thr217 (see
Table 3), which are weakened when the small isobutyl side-
chain is located in the contiguous S2 site, thus allowing more
ﬂexibility on the non-prime side of the ligand.
Fig. 4. Left: average structure from MD simulation of KNI764 (cyan) in complex with PfPMIV (yellow). The average structure is superimposed on
the 3.3 A˚ resolution electron density of 2ANL. The map is a 2Fo  Fc electron density map calculated from the 2ANL dataset with the ligand omitted
and is displayed at 1.0 r. The average structure from the MD shows a perfect match with the electron density, apart from the 2-methylbenzyl group in
P2. Right: superposition of the MD averaged structure of KNI764 (cyan) onto the crystal structure conformation from 2ANL (green). The major
diﬀerence is the ﬂipped amide bond in the P1–P2 link.
Table 3
Experimental and calculated energetics (kcal/mol) of PMIV inhibition using the AspH214 model
Complex DGobsbind (kcal/mol)
a DGcalcbind (kcal/mol) Ligand-surrounding interactions (kcal/mol)
d
hV vdwls ip hV ellsip hV vdwls iw hV ellsiw
KNI764–PmPMIV 9.6b 9.8 ± 0.7d 68.1 ± 0.5 76.1 ± 1.3 42.7 ± 0.5 61.2 ± 0.7
KNI577–PmPMIV 7.6b 7.0 ± 0.8 67.2 ± 0.8 62.6 ± 1.4 39.3 ± 0.2 56.6 ± 0.5
KNI10006–PfPMIV 10.7c 14.1 ± 0.4 77.2 ± 0.1 93.3 ± 0.7 42.9 ± 0.0 69.4 ± 0.6
KNI727–PfPMIV 8.4c 11.9 ± 0.5 74.4 ± 0.4 70.4 ± 0.4 44.9 ± 0.1 52.7 ± 0.7
aThe binding free energy calculated from experimentally determined Ki’s using DG
0
bind; exp ¼ RT lnK i.
bValues from Ref. [11].
cValues from Ref. [3].
dAverage value from two MD simulations: starting from the crystallographic coordinates and from the GOLD predicted pose.
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using the AspH214 model for the P. falciparum protein. First,
docking of KNI10006 and KNI727 was carried out using both
the 1LS5 and 2ANL structures. The same binding mode dis-
cussed above for KNI764 and KNI577 in PmPM IV was found
among the top scoring poses of KNI727 (i.e., good superposi-
tion with the conformation of KNI764 in 2ANL but with the
P2 amide bond ﬂipped). Not surprisingly, a better superposi-
tion with the crystallographic pose of KNI764 was achieved
if 2ANL was used as the rigid protein structure. Docking of
KNI10006 into 2ANL identiﬁed the same binding orientation,
although slightly displaced with respect to the native pose of
KNI764 (RMSD for backbones atoms was 1.3 A˚). On the con-
trary, when the 1LS5 protein structure was used no analogous
pose could be identiﬁed. For the following MD simulations,
the starting position of the ligand in the protein binding pocket
should be accurate enough so that the values averaged during
the MD sampling can converge within reasonable calculation
time. Therefore, we retrieved the best pose found in the dock-
ing exploration of 2ANL-KNI727 and used it for MD simula-
tions with PfPM IV. To do this, superposition of the protein
structures and, in the case of KNI10006, mutation of the P2
sidechain were performed. Again, the calculated aﬃnities using
the AspH214 model could explain the experimental diﬀerence
in aﬃnity of the two ligands. The only structural diﬀerence be-
tween this pair of molecules, the P2 sidechain, was identiﬁed as
the key to explain the diﬀerence in aﬃnity: the aminoindanol
group present in KNI10006 contributes to an enhancement
of both electrostatic and non-electrostatic interactions withthe protein, compared to the smaller isobutyl in KNI727 (see
Table 3). As was the case with PmPM IV, the comparison of
the AspH34 and AspH214 models clearly suggest that the
AspH214 model accounts for stronger interactions of the
inhibitor with the catalytic site (see Table 2).
It must be noted that, in the case of PfPM IV, it is not pos-
sible to estimate absolute binding free energies, since only the
IC50 values have been reported in this case [3]. IC50 values for
competitive inhibitors, as those used in this study, in general
are weaker in magnitude than Ki values because the concentra-
tion and aﬃnity of the substrate for the enzyme are not explic-
itly considered in the assay setup and IC50 calculations [31].
Therefore, the calculated binding free energies are expected
to be more negative than the corresponding values obtained
from IC50 experiments. Furthermore, earlier calculations on
PfPMIV inhibitors have indicated that the constant c term in
Eq. (1) is positive and about 1.5 kcal/mol for PfPMIV, while
it is zero in PfPMII [29]. The average overestimation of
3 kcal/mol in our calculations is consistent with these observa-
tions.4. Discussion
The protonation state of the catalytic aspartates in aspartic
proteases is an ambiguous and unsolved question. Several
studies have addressed this point using diﬀerent computational
[32–36] and experimental [37–39] approaches. It can be con-
cluded that no unique model exists and the location of the pro-
Fig. 5. Superposition of the structures of the four PMIV–KNI
complexes, as average coordinates of the MD trajectories sampled
for binding free energy calculations: KNI764–PmPMIV (green),
KNI577–PmPMIV (cyan), KNI10006–PfPMIV (magenta), KNI727–
PfPMIV (yellow).
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bound. As an example of the ambiguous location of the pro-
ton, two high resolution crystal structures of the HIV-1 prote-
ase in complex with allophenylnorstatine inhibitors suggest
diﬀerent protonation states. On the one hand, in the complex
with KNI764, the proton is located in Od2 of Asp25B [38],
in agreement with previous NMR studies [37]. On the other
hand, the recent crystal structure of the same protein in com-
plex with a phenylnorstatine peptidic inhibitor showed a com-
pletely diﬀerent scenario [39]. In this case, the central carbon
bearing the hydroxyl group of the inhibitor had the opposite
(R) stereochemistry as compared to KNI compounds (S) and
the proton was found on Asp25A; more surprisingly, the elec-
tron density suggested the existence of a second proton shared
by the two catalytic residues, resembling that proposed for the
free enzyme [40].
In previous works [1,2], we have deﬁned AspH34 molecular
models of the Plasmodium falciparum plasmepsins II and IV,
with the proton located on the most buried oxygen (Od1) of
Asp34. This representation allowed for an optimum H-bond-
ing network with inhibitors sharing an ethylenediol transition
state mimicking group, leading to interpretative and explana-
tory binding models. However, recent analysis of the two pro-
tonation models in PfPM IV in complex with pepstatin A did
not point to any preferred location of the proton [29].
The application of the AspH34 protonation model to the re-
cently reported structure of the PmPMIV–KNI764 complex in
binding aﬃnity calculations was inconsistent with the experi-
mental data. The reason was found in the electrostatic repul-
sion between partial negative charges of Asp214 and
carbonyl of the amide bond in P1. This result was also ob-
tained with the other three PMIV–KNI complexes examined.
Additionally, the automated docking program GOLD, which
is generally successful in the re-docking of ligands onto the
corresponding native crystal structures (including several
aspartic proteases) [16] failed in the present case. Conversely,
GOLD successfully identiﬁed the native pose of the ligand as
the top ranked solution when the location of the proton was
changed (AspH214 model). The calculated aﬃnities using the
LIE approach were extraordinarily close to the experimental
ones for the pair of PmPM IV inhibitors (KNI764 and
KNI577), and also the relative aﬃnities for the two PfPM IV
complexes (KNI727 and KNI10006) were very well repro-
duced.
The simulations also identiﬁed an important diﬀerence with
respect to the 2ANL binding mode, located in the S2 site, and
in all cases was the amide bond in P2 ﬂipped with respect to the
proposed binding mode in 2ANL, leading to a better H-bond
network with the S2 pocket (Ser79, Gly216). This was found
not only using MD relaxation of the initial crystal structure,
but also the automated docking explorations were consistent
with this conformational change. As can be appreciated in
Fig. 5, the binding mode of the four complexes is much con-
served, and in all cases is the double hydrogen bond with the
ﬂap attained. Structural superposition based on the ligand
and the catalytic aspartates of our reﬁned binding mode of
PmPM IV–KNI764 with the crystal structure of HIV-1–
KNI764 complex [38] revealed some interesting features. First,
the protonated aspartate Asp25B in HIV PR is aligned with
AspH214 in PM IV, giving additional support to our proton-
ation model. Second, the conformational change in the P2
chain observed in our MD and docking simulations allowsfor a more conserved pattern of interactions with the ﬂap.
Aspartic proteases generally show a double H-bond pattern
between the P2 and P2 0 carbonyl oxygens and the ﬂap loop(s)
[41]. However, the 2ANL structure lacks the S2-ﬂap interac-
tion, and the authors already noted this signiﬁcant diﬀerence
in the S2 conformation of KNI764 with respect to the confor-
mation adopted in HIV-1 protease [11].
The present computational study provides complementary
energetic and structural data for a recent crystal structure of
a plasmepsin in complex with inhibitor. The information
gained about the protonation state of the catalytic aspartates
and the position of the amide bond in P2 turned out to be
essential in order to reproduce the experimental binding data
(see [42] for a related case in trypsin). Using the LIE method
with the standard parameterization and the slightly modiﬁed
model of KNI inhibitors bound to PM IV, we could predict
the binding free energy diﬀerences of two pairs of inhibitors
bound to two diﬀerent orthologs of the PM IV enzyme (i.e.,
PmPM IV and PfPM IV). This result clearly supports the
robustness of the binding mode proposed in this work for
PM IV–KNI complexes. We suggest that the molecular inter-
actions described here for the binding mode of the KNI series
of inhibitors to PMIV enzymes should be considered for fur-
ther structure-based design eﬀorts.
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